Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline Review, H2 2016’, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

The report reviews pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) therapeutics and enlists all their major and minor projects

The report assesses Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AFFiRiS AG

AstraZeneca Plc

Corestem Inc

MitoDys Therapeutics Ltd

Modag GmbH

Neuropore Therapies Inc

Prana Biotechnology Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Overview 6

Therapeutics Development 7

Pipeline Products for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview 7

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics under Development by Companies 8

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Products under Development by Companies 11

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development 12

AFFiRiS AG 12

AstraZeneca Plc 13

Corestem Inc 14

MitoDys Therapeutics Ltd 15

Modag GmbH 16

Neuropore Therapies Inc 17

Prana Biotechnology Ltd 18

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

Anle-138b - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

AZD-3241 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CS-10BR05 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

NPT-20011 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

PBT-434 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

PD-01 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PD-03 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules for Neurodegenerative Disease - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by AFFiRiS AG, H2 2016 12

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by AstraZeneca Plc, H2 2016 13

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Corestem Inc, H2 2016 14

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by MitoDys Therapeutics Ltd, H2 2016 15

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Modag GmbH, H2 2016 16

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Neuropore Therapies Inc, H2 2016 17

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Prana Biotechnology Ltd, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

List of Figures

List of Figures

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports